Pacific countries need stronger health systems and wider access to the technology transforming diabetes care in wealthy countries, La Trobe University researcher Lisa Denney wrote on the Devpolicy Blog to mark World Diabetes Day on 14 November.

Dr Lisa Denney is director of the Centre for Human Security and Social Change at La Trobe University, working on political economy analysis, governance, justice and security in development.

Her youngest child was diagnosed with type 1 diabetes in Australia a year ago, she wrote. Type 1 is an autoimmune condition in which the pancreas stops producing insulin and it often begins in childhood, unlike the far more common type 2, which usually develops in adulthood when genetic and environmental factors make cells resistant to insulin.

In Australia the family had an endocrinology team, training in working out carbohydrate-to-insulin ratios for every meal, and the Australian government's National Diabetes Services Scheme, which makes continuous glucose monitors and other daily supplies more affordable, Denney wrote. Insulin pumps cost A$7,000 to A$10,000 out of pocket, but are available to families with private health insurance or who qualify for the Insulin Pump Program.

That support made her think about what happens where such systems do not exist. More than one million people live with type 1 diabetes in the World Health Organization's Western Pacific Region, which runs from high-income economies such as Japan and Australia through to Pacific island countries and territories.

The condition is heavily underdiagnosed, she wrote. Global prevalence is 115.5 per 100,000 people, but in the Western Pacific it is 43.1 per 100,000. Untreated type 1 kills quickly, through diabetic ketoacidosis, when the body cannot use glucose and produces acids that poison the blood.

The Type 1 Diabetes Index estimates that 314 people in Papua New Guinea would still be alive had they not died early of the condition, Denney wrote. Someone diagnosed at the age of 10 in PNG can expect to live to 33, compared with 69 for the population without diabetes.

Supply is a further problem. Small populations, remoteness, few customers and high transport costs make the Pacific commercially unattractive for pharmaceutical products, she wrote. Shipments can take months, ships do not always have refrigerated storage, and insulin that has warmed loses potency. Insulin is free or subsidised in many Pacific public health systems, but stockouts are common and push up commercial prices.

Those problems are especially cruel, she wrote, given that the team which worked out how to isolate and inject insulin in 1922 sold the patent for one dollar. Frederick Banting, who shared the 1923 Nobel Prize for the discovery, is said to have explained that "insulin does not belong to me, it belongs to the world". World Diabetes Day falls on his birthday.

Insulin pumps guided by a continuous glucose monitor improve long-term health, and manufacturers such as Medtronic and Insulet run access programmes for underserved populations, Denney wrote. There is scope to build on this in the Pacific through collaboration between governments, pharmaceutical companies and development partners.

The region's focus on type 2 diabetes is understandable given its far higher prevalence, and both conditions rely on some of the same medicines and supplies, she wrote.